• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Open Science

The Alliance expects all research collaborators to make their outputs (materials and knowledge) publicly available, without restriction on use, and to follow the values, principles, and practices in this Open Science Statement. They support the Alliance’s own values on open science.

The table below shows how the values, principles, and practices connect. The numbered practices that follow explain each commitment in more detail.

On this page

Values, principles, and practices  │  Open science practices

Values, principles, and practices

Open Science Statement: values, principles, and practices
Values Principles Practices
Human-centric Fairness Representative; respectful
Inclusive Communications; behaviours; driven by people living with ALS/MND and their communities (PALS/CALS)
Accountability Intellectual property (IP); auditable
Knowledge-sharing Urgency Timely
Transparency Article access
Interoperable Data and code access
Replicable and reproducible Protocols
Trustworthy Reliability Accessible documentation
Private and secure Compliance processes and guidelines
Follow-on research Re-use; attribution and acknowledgement

Practices

  1. Each researcher or project will have a plan for how the principles of open science will be followed, from the start of the project to its end. The plan will describe how the values of human-centric, knowledge-sharing, and trustworthy research will be met.
  2. Where possible, existing human data will be used, so that people living with ALS/MND and their communities do not have to undergo repeat testing if they have given informed consent for their data to be made available under open science principles.
  3. Researchers will post experimental protocols to a protocol-sharing service, such as protocols.io.
  4. All articles resulting from funding must be published in a fully open access journal or posted in an open repository with free, immediate readership rights.
  5. Researchers will seek to place open access results arising from research projects (internal or collaborative) in the public domain. In any Alliance project they undertake (internal or collaborative), researchers will not file any form of patent application or allow a collaborator to restrict the research use of open access project outputs.
  6. Data will be shared according to the FAIR principles: Findability, Accessibility, Interoperability, and Reuse of digital assets.
  7. Researchers will promptly release the associated output data through free and publicly accessible digital repositories, while continuing to comply with all applicable privacy and confidentiality regulations.
  8. Any data, code, and software needed for independent verification of research results must be curated and made freely and publicly available in an established, open repository. This must happen no later than the publication of the first paper based on the data or the end of the grant, whichever comes first.
  9. Research outputs (articles, data, code, and software) resulting from funding must be made available with broad reuse and remixing rights (for example, CC BY or CC0 licences).
  10. Applicants will be encouraged to include the anticipated costs of making their work open in their grant applications.
  11. All researchers and projects will include a data-sharing plan as part of the application process. Compliance checkpoints throughout the term of engagement will proactively collect proof of compliance with this policy, as part of interim and final reports.

Primary Sidebar

  • Elkin Gaviria, Colombia

    Elkin Gaviria, Colombia

  • Art Eggert, USA

    Art Eggert, USA

  • Shera Mukherjee, India

    Shera Mukherjee, India

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Dan Doctoroff, USA

    Dan Doctoroff, USA

  • Calum Ferguson, Scotland

    Calum Ferguson, Scotland

  • Ann Nicol, USA

    Ann Nicol, USA

  • Timothy Holman, Switzerland

    Timothy Holman, Switzerland

  • Sally Pauls, USA

    Sally Pauls, USA

  • Mark Miller, UK

    Mark Miller, UK

  • Marcel R. Wernard, Netherlands

    Marcel R. Wernard, Netherlands

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Glen Victor Peters, Australia

    Glen Victor Peters, Australia

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Yolanda Armendariz, Mexico

    Yolanda Armendariz, Mexico

  • Lombana, Spain

    Lombana, Spain

  • Maria Lucia Wood Saldanha, Brazil

    Maria Lucia Wood Saldanha, Brazil

  • Liam Dwyer, England

    Liam Dwyer, England

  • Barry de Reuver, Netherlands

    Barry de Reuver, Netherlands

  • Malu Araujo Ribeiro, Brazil

    Malu Araujo Ribeiro, Brazil

  • Teddy Hanono Annie, Mexico

    Teddy Hanono Annie, Mexico

  • Chen Chun-Chin, Malaysia

    Chen Chun-Chin, Malaysia

  • Mike Small, UK

    Mike Small, UK

  • Leon Ryba, Argentina

    Leon Ryba, Argentina

  • Antonio Ventriglia, Belgium

    Antonio Ventriglia, Belgium

  • Nicholas (Nic) Bowman, South Africa

    Nicholas (Nic) Bowman, South Africa

  • Francisco Perez Palop, Spain

    Francisco Perez Palop, Spain

  • Hanne Stenmose, Denmark

    Hanne Stenmose, Denmark

  • Shay Rishoni, Netherlands

    Shay Rishoni, Netherlands

  • Bob Spurrier, USA

    Bob Spurrier, USA

  • Chris McCauley, Canada

    Chris McCauley, Canada

  • Frank Bos, Netherlands

    Frank Bos, Netherlands

  • Mike Cels, Canada

    Mike Cels, Canada

  • Jose Espinosa, Argentina

    Jose Espinosa, Argentina

  • Ywan Dierick, Belgium

    Ywan Dierick, Belgium

  • Dorette Lüdi, Switzerland

    Dorette Lüdi, Switzerland

  • Ali Var, Turkey

    Ali Var, Turkey

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Dawn Morton, Scotland

    Dawn Morton, Scotland

  • Steven Spencer, New Zealand

    Steven Spencer, New Zealand

  • JP

    JP

  • Carlos Gomez Matallanas, Spain

    Carlos Gomez Matallanas, Spain

  • Mahmood Anwar, UK

    Mahmood Anwar, UK

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • Glen Elison, USA

    Glen Elison, USA

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • David Hall, USA

    David Hall, USA

  • Natalya Rybakova, Russia

    Natalya Rybakova, Russia

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login